SMTI vs. MDXG, INMD, BBNX, KMTS, IRMD, SIBN, CBLL, EMBC, AVNS, and RXST
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include MiMedx Group (MDXG), InMode (INMD), Beta Bionics (BBNX), Kestra Medical Technologies (KMTS), iRadimed (IRMD), SiBone (SIBN), CeriBell (CBLL), Embecta (EMBC), AVANOS MEDICAL (AVNS), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Sanara MedTech vs. Its Competitors
Sanara MedTech (NASDAQ:SMTI) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
In the previous week, MiMedx Group had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for MiMedx Group and 0 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.00 equaled MiMedx Group'saverage media sentiment score.
Sanara MedTech has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.
Sanara MedTech currently has a consensus target price of $49.50, indicating a potential upside of 65.69%. MiMedx Group has a consensus target price of $12.50, indicating a potential upside of 98.89%. Given MiMedx Group's higher possible upside, analysts plainly believe MiMedx Group is more favorable than Sanara MedTech.
MiMedx Group has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 42.6% of Sanara MedTech shares are held by insiders. Comparatively, 1.7% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MiMedx Group has a net margin of 11.40% compared to Sanara MedTech's net margin of -12.48%. MiMedx Group's return on equity of 22.70% beat Sanara MedTech's return on equity.
Summary
MiMedx Group beats Sanara MedTech on 11 of the 13 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
This page (NASDAQ:SMTI) was last updated on 7/3/2025 by MarketBeat.com Staff
